Treatment with the CLL-1 TriKE efficiently inhibited the NK-mediated killing of CLL-1-expressing AML cell lines, as well as primary AML blasts and LSCs, in an antigen-dependent manner. The gene discussed is CLEC12A; the disease is acute myeloid leukemia.